2013 Q2 Form 10-K Financial Statement
#000114420413053105 Filed on September 30, 2013
Income Statement
| Concept | 2013 Q2 | 2013 | 2012 Q2 |
|---|---|---|---|
| Revenue | $620.0K | $1.007M | $350.0K |
| YoY Change | 77.14% | -21.14% | 2.94% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $950.0K | $3.910M | $1.360M |
| YoY Change | -30.15% | -26.23% | -47.89% |
| % of Gross Profit | |||
| Research & Development | $970.0K | $3.431M | $1.050M |
| YoY Change | -7.62% | -31.12% | -10.26% |
| % of Gross Profit | |||
| Depreciation & Amortization | $90.00K | $2.000K | $90.00K |
| YoY Change | 0.0% | -71.43% | -10.0% |
| % of Gross Profit | |||
| Operating Expenses | $1.920M | $7.674M | $2.500M |
| YoY Change | -23.2% | -27.63% | -35.4% |
| Operating Profit | -$6.667M | ||
| YoY Change | -28.52% | ||
| Interest Expense | -$20.00K | $90.00K | $780.0K |
| YoY Change | -102.56% | 42.86% | -59.79% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $10.00K | $469.0K | $0.00 |
| YoY Change | -100.0% | ||
| Pretax Income | -$1.320M | -$6.200M | -$1.360M |
| YoY Change | -2.94% | 9.15% | -13.92% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$1.320M | -$6.198M | -$1.360M |
| YoY Change | -2.94% | 9.2% | -13.92% |
| Net Earnings / Revenue | -212.9% | -615.49% | -388.57% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$243.5K | -$1.255M | -$375.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | |||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2013 Q2 | 2013 | 2012 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $4.410M | $4.410M | $5.620M |
| YoY Change | -21.53% | -21.53% | 97.89% |
| Cash & Equivalents | $4.414M | $5.624M | |
| Short-Term Investments | |||
| Other Short-Term Assets | $31.00K | $1.210M | $750.0K |
| YoY Change | -95.87% | 61.33% | -2.6% |
| Inventory | |||
| Prepaid Expenses | $31.00K | $5.000K | |
| Receivables | $1.007M | $1.010M | $351.0K |
| Other Receivables | $0.00 | $0.00 | $180.0K |
| Total Short-Term Assets | $6.635M | $6.640M | $6.900M |
| YoY Change | -3.84% | -3.77% | 60.47% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $6.000K | $10.00K | $3.000K |
| YoY Change | 100.0% | -70.0% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $2.713M | $2.862M | |
| YoY Change | -5.21% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $2.719M | $2.710M | $2.865M |
| YoY Change | -5.1% | -5.57% | -5.76% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $6.635M | $6.640M | $6.900M |
| Total Long-Term Assets | $2.719M | $2.710M | $2.865M |
| Total Assets | $9.354M | $9.350M | $9.765M |
| YoY Change | -4.21% | -4.3% | 33.04% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.401M | $2.400M | $2.846M |
| YoY Change | -15.64% | -15.79% | -1.86% |
| Accrued Expenses | $1.885M | $1.890M | $230.0K |
| YoY Change | 719.57% | 721.74% | 283.33% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $4.286M | $4.290M | $3.596M |
| YoY Change | 19.19% | 19.17% | -49.64% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.286M | $4.290M | $3.596M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $4.290M | $4.290M | $3.600M |
| YoY Change | 19.17% | 19.17% | -49.58% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$37.54M | -$31.34M | |
| YoY Change | 19.78% | ||
| Common Stock | $42.60M | $37.51M | |
| YoY Change | 13.59% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $5.068M | $5.070M | $6.169M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $9.354M | $9.350M | $9.765M |
| YoY Change | -4.21% | -4.3% | 33.04% |
Cashflow Statement
| Concept | 2013 Q2 | 2013 | 2012 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.320M | -$6.198M | -$1.360M |
| YoY Change | -2.94% | 9.2% | -13.92% |
| Depreciation, Depletion And Amortization | $90.00K | $2.000K | $90.00K |
| YoY Change | 0.0% | -71.43% | -10.0% |
| Cash From Operating Activities | -$910.0K | -$4.849M | -$1.040M |
| YoY Change | -12.5% | -19.32% | -5.45% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$40.00K | $7.000K | -$60.00K |
| YoY Change | -33.33% | 600.0% | -154.55% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$40.00K | -$195.0K | -$60.00K |
| YoY Change | -33.33% | -20.41% | -154.55% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $4.284M | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.830M | $3.834M | 0.000 |
| YoY Change | -57.57% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -910.0K | -$4.849M | -1.040M |
| Cash From Investing Activities | -40.00K | -$195.0K | -60.00K |
| Cash From Financing Activities | 3.830M | $3.834M | 0.000 |
| Net Change In Cash | 2.880M | -$1.210M | -1.100M |
| YoY Change | -361.82% | -143.51% | 11.11% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$910.0K | -$4.849M | -$1.040M |
| Capital Expenditures | -$40.00K | $7.000K | -$60.00K |
| Free Cash Flow | -$870.0K | -$4.856M | -$980.0K |
| YoY Change | -11.22% | -19.21% | -19.01% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013 | dei |
Trading Symbol
TradingSymbol
|
IBIO | |
| CY2013Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
56692095 | shares |
| CY2013 | dei |
Entity Registrant Name
EntityRegistrantName
|
iBio, Inc. | |
| CY2013 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001420720 | |
| CY2013 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2012Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47767095 | shares |
| CY2013 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2013 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2012Q4 | dei |
Entity Public Float
EntityPublicFloat
|
18250000 | USD |
| CY2013Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
20000 | USD |
| CY2012Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
19000 | USD |
| CY2013Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | shares |
| CY2013Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2013Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2012Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2013Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
56692095 | shares |
| CY2013Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
56692095 | shares |
| CY2012Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47767095 | shares |
| CY2013Q2 | ibio |
Prepaid Expenses Related Party
PrepaidExpensesRelatedParty
|
0 | USD |
| CY2012Q2 | ibio |
Prepaid Expenses Related Party
PrepaidExpensesRelatedParty
|
846000 | USD |
| CY2013Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
93000 | USD |
| CY2012Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
2524000 | USD |
| CY2013Q2 | us-gaap |
Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
|
0 | USD |
| CY2012Q2 | us-gaap |
Due To Other Related Parties Classified Current
DueToOtherRelatedPartiesClassifiedCurrent
|
100000 | USD |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2013Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2013Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2013Q2 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
| CY2012Q2 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
| CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4414000 | USD |
| CY2012Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5624000 | USD |
| CY2013Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1007000 | USD |
| CY2012Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
351000 | USD |
| CY2013Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1214000 | USD |
| CY2012Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
925000 | USD |
| CY2013Q2 | us-gaap |
Assets Current
AssetsCurrent
|
6635000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6198000 | USD |
| CY2012Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3596000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2612000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1263000 | USD |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y6M | |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4981000 | USD |
| CY2012 | us-gaap |
Operating Expenses
OperatingExpenses
|
10604000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9327000 | USD |
| CY2012 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12000 | USD |
| CY2012 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
34000 | USD |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39506 | shares |
| CY2013 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
336000 | USD |
| CY2012Q2 | us-gaap |
Assets Current
AssetsCurrent
|
6900000 | USD |
| CY2013Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6000 | USD |
| CY2012Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3000 | USD |
| CY2013Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2713000 | USD |
| CY2012Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2862000 | USD |
| CY2013Q2 | us-gaap |
Assets
Assets
|
9354000 | USD |
| CY2012Q2 | us-gaap |
Assets
Assets
|
9765000 | USD |
| CY2013Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2401000 | USD |
| CY2012Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2846000 | USD |
| CY2013Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1885000 | USD |
| CY2012Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
230000 | USD |
| CY2013Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | USD |
| CY2012Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
520000 | USD |
| CY2013Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4286000 | USD |
| CY2013Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2012Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
| CY2013Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
57000 | USD |
| CY2012Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
48000 | USD |
| CY2013Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
42547000 | USD |
| CY2012Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
37459000 | USD |
| CY2013Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-37536000 | USD |
| CY2012Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-31338000 | USD |
| CY2013Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5068000 | USD |
| CY2012Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6169000 | USD |
| CY2013Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9354000 | USD |
| CY2012Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9765000 | USD |
| CY2013 | ibio |
Research And Development Related Party
ResearchAndDevelopmentRelatedParty
|
424000 | USD |
| CY2012 | ibio |
Research And Development Related Party
ResearchAndDevelopmentRelatedParty
|
4216000 | USD |
| CY2013 | ibio |
General And Administrative Related Party
GeneralAndAdministrativeRelatedParty
|
0 | USD |
| CY2012 | ibio |
General And Administrative Related Party
GeneralAndAdministrativeRelatedParty
|
200000 | USD |
| CY2013 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
0 | USD |
| CY2012 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
62000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1007000 | USD |
| CY2012 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1277000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3431000 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4243000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5623000 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
7674000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6667000 | USD |
| CY2013 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
9000 | USD |
| CY2013 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
34000 | USD |
| CY2013 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
520000 | USD |
| CY2012 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
3668000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5676000 | USD |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.14 | |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
49381 | shares |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
90000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
63000 | USD |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4000 | USD |
| CY2012 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
0 | USD |
| CY2011Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
196000 | USD |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6760000 | shares |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
6736548 | shares |
| CY2012 | ibio |
Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
|
9037000 | USD |
| CY2013 | ibio |
Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
|
3834000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
2000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
7000 | USD |
| CY2012 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
323000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1263000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2683000 | USD |
| CY2013 | ibio |
Vendor Concession Related Party
VendorConcessionRelatedParty
|
0 | USD |
| CY2012 | ibio |
Vendor Concession Related Party
VendorConcessionRelatedParty
|
100000 | USD |
| CY2013 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | USD |
| CY2012 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
87000 | USD |
| CY2013 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
3000 | USD |
| CY2012 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
0 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
656000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7000 | USD |
| CY2013 | ibio |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
289000 | USD |
| CY2012 | ibio |
Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
|
-88000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-445000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-50000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1655000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
103000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
188000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
244000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-195000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-245000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
3834000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
9036000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3834000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9036000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1210000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2781000 | USD |
| CY2011Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2843000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4849000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6010000 | USD |
| CY2013 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | pure |
| CY2013 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b> 1.</b></div> </td> <td> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b>Nature of Business</b></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">iBio, Inc. (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch™ platform for vaccines and therapeutic proteins and the iBioModulator™ platform for vaccine enhancement – and on developing and commercializing select product candidates derived from the iBioLaunch platform. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or impossible to produce with conventional methods, reduced production time, and lower capital and operating costs for biopharmaceuticals. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in <font style=" FONT-SIZE: 10pt">one</font> business segment under the direction of its Executive Chairman, and its operations and assets reside exclusively in the United States.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Reclassifications</em></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior-period amounts have been reclassified to conform to the current period presentation. Prepaid expenses and other current assets have been combined for presentation in the accompanying balance sheets and statements of cash flows. Depreciation and amortization expenses have been separated in the accompanying statements of cash flows. Share-based compensation expenses have been combined in the accompanying statements of cash flows.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2012Q2 | us-gaap |
Share Price
SharePrice
|
0.76 | |
| CY2013 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0004 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.002 | pure |
| CY2013 | us-gaap |
Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
|
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Derivative Instruments</em></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company does not use derivative instruments in its ordinary course of business. Some of the Company’s outstanding warrants contain an anti-dilution provision which qualifies as an embedded derivative and must be accounted for separately as a derivative liability. This liability is recognized on the balance sheet at fair value each reporting period, and changes in the fair value are charged to other income or expense, as appropriate, and reflected in the current period earnings.</div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><em><em>Use of Estimates</em></em></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies, a warrant derivative liability and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013Q2 | us-gaap |
Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
|
0 | USD |
| CY2012Q2 | us-gaap |
Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
|
520000 | USD |
| CY2013Q2 | us-gaap |
Share Price
SharePrice
|
0.42 | |
| CY2013Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
77000 | USD |
| CY2012Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
74000 | USD |
| CY2013Q2 | ibio |
Other Receivables Related Party Reimbursable Patent Costs
OtherReceivablesRelatedPartyReimbursablePatentCosts
|
0 | USD |
| CY2012Q2 | ibio |
Other Receivables Related Party Reimbursable Patent Costs
OtherReceivablesRelatedPartyReimbursablePatentCosts
|
179000 | USD |
| CY2013Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
31000 | USD |
| CY2012Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
5000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
2713000 | USD |
| CY2012Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
2862000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
4969000 | USD |
| CY2012Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
4784000 | USD |
| CY2012Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1922000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2256000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
343000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
343000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
328000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
312000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
288000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
1099000 | USD |
| CY2013Q2 | ibio |
Consulting Fees
ConsultingFees
|
71000 | USD |
| CY2012Q2 | ibio |
Consulting Fees
ConsultingFees
|
71000 | USD |
| CY2013Q2 | ibio |
Public Company Costs
PublicCompanyCosts
|
45000 | USD |
| CY2012Q2 | ibio |
Public Company Costs
PublicCompanyCosts
|
0 | USD |
| CY2013Q2 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
44000 | USD |
| CY2012Q2 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
41000 | USD |
| CY2013Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
25000 | USD |
| CY2012Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
18000 | USD |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
20940796 | shares |
| CY2013Q1 | ibio |
At Market Equity Offering Sales Agreement Authorized Amount
AtMarketEquityOfferingSalesAgreementAuthorizedAmount
|
10000000 | USD |
| CY2013Q1 | ibio |
At Market Equity Offering Sales Agreement Commission Percentage
AtMarketEquityOfferingSalesAgreementCommissionPercentage
|
0.03 | pure |
| CY2013Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
121000 | USD |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.979 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
1.0 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P2M12D | |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P1Y2M12D | |
| CY2013Q2 | us-gaap |
Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
|
10000000 | shares |
| CY2013Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
25400000 | shares |
| CY2008Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
4200000 | shares |
| CY2008Q3 | ibio |
Class Of Warrant Or Right Increase In Numbers
ClassOfWarrantOrRightIncreaseInNumbers
|
800000 | USD |
| CY2013Q2 | ibio |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
|
25395940 | shares |
| CY2012Q2 | ibio |
Warrants Outstanding Exercise Price Per Share
WarrantsOutstandingExercisePricePerShare
|
1.39 | |
| CY2013Q2 | ibio |
Warrants Outstanding Exercise Price Per Share
WarrantsOutstandingExercisePricePerShare
|
1.23 | |
| CY2013Q2 | ibio |
Weighted Average Exercise Price Per Share Warrants Exercisable
WeightedAverageExercisePricePerShareWarrantsExercisable
|
1.23 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
|
25395940 | shares |
| CY2013 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
6700000 | shares |
| CY2012 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
25400000 | shares |
| CY2013 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
5500000 | shares |
| CY2012 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
20900000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y | |
| CY2008Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
10000000 | shares |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
3200000 | shares |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
2500000 | USD |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
700000 | USD |
| CY2013Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2000000 | USD |
| CY2013 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7M6D | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.90 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.56 | |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1263000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2683000 | USD |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5510000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1330000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
80000 | shares |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4266604 | shares |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.56 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.02 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
1.55 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.45 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1.45 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.54 | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y6M | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P7Y | |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
494000 | USD |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
161000 | USD |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
161000 | USD |
| CY2013Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
139000 | USD |
| CY2008Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5500000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
28900000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
17700000 | USD |
| CY2013Q2 | ibio |
Deferred Tax Asset Research And Development Credit
DeferredTaxAssetResearchAndDevelopmentCredit
|
737000 | USD |
| CY2013 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-2447000 | USD |
| CY2012 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-2802000 | USD |
| CY2013 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-366000 | USD |
| CY2012 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-417000 | USD |
| CY2013 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
-2813000 | USD |
| CY2012 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
-3219000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
10856000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
8532000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3198000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2682000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
737000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
400000 | USD |
| CY2013Q2 | ibio |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accounts Payable
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccountsPayable
|
0 | USD |
| CY2012Q2 | ibio |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accounts Payable
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccountsPayable
|
140000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
|
-56000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses
|
172000 | USD |
| CY2013Q2 | ibio |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Vacation Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsVacationAccruals
|
18000 | USD |
| CY2012Q2 | ibio |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Vacation Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsVacationAccruals
|
14000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
0 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
0 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
14753000 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11940000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2012Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.03 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.26 | pure |
| CY2013 | ibio |
Effective Income Tax Rate Reconciliation Research And Development Tax Credit
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTaxCredit
|
0.04 | pure |
| CY2012 | ibio |
Effective Income Tax Rate Reconciliation Research And Development Tax Credit
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTaxCredit
|
0.07 | pure |
| CY2013 | ibio |
Effective Income Tax Rate Non Utilization Of State Operating Loss
EffectiveIncomeTaxRateNonUtilizationOfStateOperatingLoss
|
0 | pure |
| CY2012 | ibio |
Effective Income Tax Rate Non Utilization Of State Operating Loss
EffectiveIncomeTaxRateNonUtilizationOfStateOperatingLoss
|
-0.12 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.02 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.04 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.45 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.57 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2012 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
-2813000 | USD |
| CY2012 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
-3219000 | USD |
| CY2012 | us-gaap |
Interest Revenue Expense Net
InterestRevenueExpenseNet
|
1300000 | USD |
| CY2010Q4 | us-gaap |
Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
|
1700000 | USD |
| CY2013Q2 | ibio |
Long Term Purchase Commitment Total Payments
LongTermPurchaseCommitmentTotalPayments
|
10000000 | USD |
| CY2013 | ibio |
Long Term Purchase Commitment Payment Frequency
LongTermPurchaseCommitmentPaymentFrequency
|
semi-annual | |
| CY2013 | ibio |
Long Term Purchase Commitment Payment Amount
LongTermPurchaseCommitmentPaymentAmount
|
1000000 | USD |
| CY2013 | us-gaap |
Long Term Purchase Commitment Time Period
LongTermPurchaseCommitmentTimePeriod
|
15 years | |
| CY2013 | us-gaap |
Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
|
200000 | USD |
| CY2013 | ibio |
Long Term Purchase Commitment Expire Date
LongTermPurchaseCommitmentExpireDate
|
2015-12-31 |
